Loading stock data…
Tvardi Therapeutics (TVRD)
$2.51-0.05 (-1.95%)
Market ClosedLast close Jul 24
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tvardi Therapeutics, Inc. in the Healthcare sector is trading at $2.51 with a market capitalization of $24M. Wall Street consensus targets $9.75 (8 analysts), implying a +288.4% move over the next 12 months. The stock is currently near its 52-week low of $1.50, remaining 44.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +288.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | $2.57M |
| Operating Income | -$7.05M↑ | -$7.59M↓ | -$5.94M↑ | -$8.87M↓ | -$4.35M |
| Net Income | -$6.80M↑ | -$7.28M↓ | -$5.53M↓ | $4.17M↑ | -$9.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferativ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$24.44M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-106.44%
Volume
Today's trading volume
332,191
Recent News
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.
Sector Update: Healthcare Stocks Lower Wednesday Afternoon
Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index and the State Street
Top Midday Gainers
Raymond James upgraded the shares of Tvardi Therapeutics (TVRD) to outperform from market perform.
Sector Update: Health Care Stocks Fall Late Afternoon
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the
We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...